Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, adult, Translational Research, Non-Biological therapies, MPN, epidemiology, elderly, Clinical Research, Chemotherapy, health outcomes research, drug development, Chronic Myeloid Malignancies, patient-reported outcomes, Diseases, Therapies, Immunotherapy, Adverse Events, young adult , Myeloid Malignancies, Pharmacology, Study Population, Human
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, adult, Translational Research, Non-Biological therapies, MPN, epidemiology, elderly, Clinical Research, Chemotherapy, health outcomes research, drug development, Chronic Myeloid Malignancies, patient-reported outcomes, Diseases, Therapies, Immunotherapy, Adverse Events, young adult , Myeloid Malignancies, Pharmacology, Study Population, Human
Monday, December 12, 2022: 10:30 AM-12:00 PM
217-219
(Ernest N. Morial Convention Center)
Moderators:
Mary Frances McMullin, MD, FRCPath, FRCP, Queen's University, Belfast
and
Jean-Jacques Kiladjian, MD, Hopital Saint-Louis
Disclosures:
McMullin: Novartis: Consultancy, Speakers Bureau; BMS: Consultancy, Research Funding; AOP: Research Funding, Speakers Bureau; CTI: Consultancy; Sierra Oncology: Consultancy; Incyte: Consultancy, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Pfizer: Speakers Bureau. Kiladjian: Novartis: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; AOP Orphan: Membership on an entity's Board of Directors or advisory committees.
In this session results of clinical trials and translational research in ET and PV is presented including some provocative data for correlating outcomes of patients with change in JAK2 V617F allele burden
10:30 AM
10:45 AM
11:00 AM
11:15 AM
11:30 AM
11:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH